What is NDC 72359-001?

72359-001 is the product NDC for Rethymic, Allogeneic thymocyte-depleted thymus tissue-agdc 22000 mm/1 implant, listed with the FDA by Sumitomo Pharma America, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

What drug is associated with this NDC?

Rethymic (Allogenic thymocyte-depleted thymus tissue-agdc).

What is the active ingredient?

Allogeneic thymocyte-depleted thymus tissue-agdc.

Sumitomo Pharma America, Inc., NDC labeler code 72359. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Rethymic?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Rethymic NDC 72359-001 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)72359-001Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72359-0001Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72359-001-01	7235900010172359000101	11 CONTAINER in 1 BOX (72359-001-01) / 4 IMPLANT in 1 CONTAINER (72359-001-02)Marketed from Oct 8, 2021

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Rethymic
Generic name (nonproprietary): allogenic thymocyte-depleted thymus tissue-agdc
Active ingredients: Allogeneic thymocyte-depleted thymus tissue-agdc — 22000 mm/1
Dosage form: Implant
Route: Intramuscular
Labeler: Sumitomo Pharma America, Inc.NDC labeler code 72359
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 125685
Marketing start: Oct 8, 2021
Listing expires: Dec 31, 2026
Identifiers: Product ID 72359-001_6b1c53ef-4ff9-46ff-96ad-b0cb5609ec17SPL ID 6b1c53ef-4ff9-46ff-96ad-b0cb5609ec17SPL set ID e0022c28-8cda-4f1e-bcf1-1f440d37ec4aRxCUI 2626464, 2626469UNII XD66YK3YY3UPC 0372359001015

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N472359000101 followed by a unit qualifier and the quantity

Package 72359-0001-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 31, 2025.

Indications (excerpt from the label)

RETHYMIC ® is indicated for immune reconstitution in pediatric patients with congenital athymia. RETHYMIC is indicated for immune reconstitution in pediatric patients with congenital athymia. ( 1 ) Limitations of Use : RETHYMIC is not indicated for the treatment of patients with severe combined immunodeficiency (SCID). Limitations of Use RETHYMIC is not indicated for the treatment of patients with severe combined immunodeficiency (SCID).

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 72359-001

What is NDC 72359-001?: 72359-001 is the product NDC for Rethymic, Allogeneic thymocyte-depleted thymus tissue-agdc 22000 mm/1 implant, listed with the FDA by Sumitomo Pharma America, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Rethymic (Allogenic thymocyte-depleted thymus tissue-agdc).
What is the active ingredient?: Allogeneic thymocyte-depleted thymus tissue-agdc.
Who is the labeler?: Sumitomo Pharma America, Inc., NDC labeler code 72359. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Rethymic?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.